IPO Timeline Raw facts
Company Overview
| Stock Name | Brainaurora-B |
|---|---|
| Stock Code | 06681 |
| Company Full Name | BrainAurora Medical Technology Limited |
| Industry | 醫療保健 |
| Principal Activities | 公司是中國認知障礙數字療法(「數字療法」)市場的資深參與者,是中國首家將腦科學與先進的人工智能(「AI」)技術相結合,開發出針對認知障礙的醫療級數字療法產品的公司。 |
| Listing Date | 2025-01-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省紹興市越城區平江路2號紹興水木灣區科學園3號樓13層1301 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.66nao.cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 3.22 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 3,220 |
| Par Value | To be extracted |
| Offer Period | 2024-12-30 to 2025-01-03 |
| Global Offering Shares | 181,112,000 shares |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 64.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 583,180,640 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 3,220 |
| 2 lots | 2,000 | HK$ 6,440 |
| 3 lots | 3,000 | HK$ 9,660 |
| 4 lots | 4,000 | HK$ 12,880 |
| 5 lots | 5,000 | HK$ 16,100 |
| 6 lots | 6,000 | HK$ 19,320 |
| 7 lots | 7,000 | HK$ 22,540 |
| 8 lots | 8,000 | HK$ 25,760 |
| 9 lots | 9,000 | HK$ 28,980 |
| 10 lots | 10,000 | HK$ 32,200 |
| 15 lots | 15,000 | HK$ 48,300 |
| 20 lots | 20,000 | HK$ 64,400 |
| 25 lots | 25,000 | HK$ 80,500 |
| 30 lots | 30,000 | HK$ 96,600 |
| 35 lots | 35,000 | HK$ 112,700 |
| 40 lots | 40,000 | HK$ 128,800 |
| 45 lots | 45,000 | HK$ 144,900 |
| 50 lots | 50,000 | HK$ 161,000 |
| 60 lots | 60,000 | HK$ 193,200 |
| 70 lots | 70,000 | HK$ 225,400 |
| 80 lots | 80,000 | HK$ 257,600 |
| 90 lots | 90,000 | HK$ 289,800 |
| 100 lots | 100,000 | HK$ 322,000 |
| 200 lots | 200,000 | HK$ 644,000 |
| 300 lots | 300,000 | HK$ 966,000 |
| 400 lots | 400,000 | HK$ 1,288,000 |
| 500 lots | 500,000 | HK$ 1,610,000 |
| 600 lots | 600,000 | HK$ 1,932,000 |
| 700 lots | 700,000 | HK$ 2,254,000 |
| 800 lots | 800,000 | HK$ 2,576,000 |
| 1,000 lots | 1,000,000 | HK$ 3,220,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 2,000,000 | HK$ 6,440,000 |
| 3,000 lots | 3,000,000 | HK$ 9,660,000 |
| 8,000 lots | 8,000,000 | HK$ 25,760,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 3.61B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | RMB 57.58 million |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 3.33 |
|---|---|
| First Day Open | HK$ 3.22 |
| First Day Change | -0.93% |
| First Day Volume | 18896100.0 |
| First Day Turnover | 61637900.0 |
| Use of Proceeds | 1、所得款項凈額的約40.0%,預計將用于開展進一步研發活動、推進更多適應癥的臨床試驗及推動核心產品系統的銷售及分銷活動;
2、所得款項凈額的約16.5%,預計將用于幫助國內更多醫院建立新認知中心;
3、所得款項凈額的約15.0%,預計將用于加強公司的AI及相關技術能力;
4、所得款項凈額的約5.0%,預計將用于加快公司現有產品管線內外其他候選產品的研發及商業化進度;
5、所得款項凈額的約15.0%,預計將用于與學術機構及醫院合作的腦科學及數字療法研究中心;
6、所得款項凈額的約8.5%,預計將用作公司的營運資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
达维律师事务所 通商律师事务所 汇嘉律师事务所(香港) |
| Legal Advisor to Sponsors/Underwriters |
科律香港律师事务所 中伦律师事务所 |
| Auditor and Reporting Accountant | 德勤•关黄陈方会计师行 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Compliance Advisor | SPDB International Capital Limited CE BFZ375 |
| Receiving Banks | 招商永隆银行有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 黄光伟 | 31,101,980 HKD | — | 5.33% | — | 6 months | 2025-07-08 |
| 2 | 苏州策源扶海企业管理合伙企业(有限合伙) | 227,090,500 HKD | — | 38.94% | — | 6 months | 2025-07-08 |
| 3 | 天士力(国际)医疗健康投资发展有限公司 | 77,756,560 HKD | — | 13.33% | — | 6 months | 2025-07-08 |
| 4 | 天士力(香港)医药投资有限公司 | 38,878,280 HKD | — | 6.67% | — | 6 months | 2025-07-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 譚錚 | — |
| Company Secretary | 王俊杰,岑影文 | — |
Major Shareholders
| Major Shareholders & Holdings | ZTan Limited(21.75%),Crusky Limited(9.76%),NLVF(9.14%),Wispirits Limited(8.61%),Healthblooming Limited(7.83%) |
|---|
Market Sentiment
The IPO saw a modest oversubscription of 11.39 times, paired with a high hit rate of 68.57%, reflecting tepid investor enthusiasm. The reallocation from the international tranche to the Hong Kong public offering further underscores weaker-than-expected demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
The top of the A-tier (甲尾) and the bottom of the B-tier (乙头) both anticipated a single lot, despite application amounts of HK$1,000,000 and HK$2,000,000 respectively. This indicates that the B-head allocation was disproportionately costly, reducing efficiency for larger subscribers. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Mainland Chinese investors dominated the applicant pool at 87.6%, signaling strong cross-border demand for this biotech listing. The demographic profile skews male (62.3%) with an average age of 43, typical of experienced investors in this segment. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




